Hamilton Lane Advisors’s AnaptysBio ANAB Stock Holding History

Hamilton Lane Advisors’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-41,017	Closed	-$882K	–	68
2020 Q4	$882K	Buy	+41,017	New	+$996K	0.33%	36
2018 Q3	–	Sell	-47,395	Closed	-$3K	–	47
2018 Q2	$3K	Buy	+47,395	New	+$3.98M	2.73%	9
2017 Q4	–	Sell	-74,163	Closed	-$2.59M	–	56
2017 Q3	$2.59M	Buy	+74,163	New	+$2M	1.78%	14

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hamilton Lane Advisors's ANAB Position: Q1 2021 in Review

Hamilton Lane Advisors sold out of AnaptysBio (ANAB) in Q1 2021, closing a stake of 41,017 shares — an estimated $882K sold.

Hamilton Lane Advisors first reported a position in ANAB in Q3 2017 and held it in 3 quarters. The position peaked at $2.59M in Q3 2017. 122 funds tracked by Wall St. Rank hold ANAB as of Q1 2021.

Hamilton Lane Advisors reported no remaining AnaptysBio position as of Q1 2021 after selling out during the quarter.
Hamilton Lane Advisors sold 41,017 AnaptysBio shares in Q1 2021, an estimated $882K.
Hamilton Lane Advisors first reported a position in AnaptysBio in Q3 2017 and held it in 3 quarters.
Hamilton Lane Advisors's AnaptysBio position peaked at $2.59M in Q3 2017.
122 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2021.

Based on Hamilton Lane Advisors's 13F filing for Q1 2021, filed 13 Apr 2021.